3 / 8
Page 31
Notes:
Journal of Clinical & Experimental Pathology | ISSN: 2161-0681 | Volume 8
Breast Pathology and Cancer Diagnosis
6
th
World Congress and Expo on
July 25-26, 2018 | Vancouver, Canada
Medicinal Chemistry and Rational Drugs
20
th
International Conference on
&
Extremely potent, pan-genotypic Hepatitis C virus NS5A inhibitors based on novel core structures
H
epatitis C virus (HCV) infection often leads to serious liver diseases such as cirrhosis followed eventually by hepatocellular
carcinoma. Several HCV RNA gene products (NS2, NS3, NS4A, NS4B, NS5A and NS5B) involved in the reproduction of
HCV have been instensively studied for new therapeutic target identification. Recently, combinations of direct acting antivirals
(DAA) including HCV NS3/4A protease inhibitors such as boceprevir, telaprevir, paritaprevir, and grazoprevir, polymerase
inhibitors such as sofosbuvir and dasabuvir, and NS5A inhibitors such as daclatasvir, ledipasvir, ombitasvir, elbasvir and
velpatasvir have shown successful arrest of the infection. However, even with the new DAA’s, resistance to the drugs in patients
infected with various strains of HCV has emerged. Therefore development of effective anti-HCV drug candidates possessing
pan-genotype activities is still needed. Herein we report the discovery of a series of extremely potent HCV NS5A inhibitors
based on a few new core skeletons. From these efforts, we have identified a series of NS5A inhibitors that exhibit highly potent
anti-HCV activities particularly against several genetic variants and some mutant strains. Several interesting compounds were
further evaluated with other studies and are shown to be nontoxic and anticipated to be effective HCV drug candidates.
Biography
B Moon Kim has completed his PhD and postdoctoral studies at M.I.T. After 5 year experience at Merck Research Laboratories in USA, he took a faculty position at
the Chemistry Department of Seoul Naitonal University Korea. He was Chemistry Department Chair and Director of the BK21 Chemistry & Molecular Engineering
Division at SNU. He has published more than 120 papers and 25 patents and has been serving as an editorial board member of Bioorganic Medicinal Chemistry
and Bioorgnaic & Medicinal Chemistry Letters and an editor-in-chief of Bulletin of the Korean Chemical Society.
kimbm@snu.ac.krB Moon Kim
Seoul National University, Republic of Korea
B Moon Kim, J Clin Exp Pathol 2018, Volume 8
DOI: 10.4172/2161-0681-C3-050